Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026.
Relay shares had been under pressure since October when initial results from VIKTORIA-1’s wild-type cohort exceeded market ...
Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results